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Falsely Elevated Thyroglobulin in a Patient with Thyroid Cancer and Rheumatoid Arthritis after 
Adalimumab Therapy
Archana Purushothaman, Nicholas Lintel, Kaitlin Brau, Whitney Goldner
Mentor: Whitney Goldner
Program: Diabetes, Endocrinology, and 
Metabolism
Introduction: Thyroglobulin (TG) elevation 
is used as a tumor marker for evidence 
of recurrence or metastatic disease of 
thyroid carcinoma.TG assays are usually 
immunoassays which are subject to a number 
of interferences. 
Case: We report a middle-aged patient with 
rheumatoid arthritis (RA) and Follicular 
Variant of Papillary Thyroid Carcinoma, 
AJCC 7, stage T2N0M0, status post total 
thyroidectomy and RAI ablation, with ATA 
excellent response to therapy. Ten years after 
diagnosis, the patient presented with sudden 
elevation in TG of 111 ng/mL. On repeat 
testing, TG ranged from 111-300 ng/mL with 
undetectable TG ab. Imaging did not reveal 
evidence of recurrent disease. On further 
investigation, the patient reported starting 
adalimumab for rheumatoid arthritis one-year 
prior. Tenfold dilution of the sample showed 
a decrease in TG from 300 to 47 ng/mL in a 
non-linear manner, suggestive of interference. 
The serum was treated with blocking agents 
and the TG decreased to 2.7 ng/mL suggesting 
the presence of HAMA. TG testing via mass 
spectrometry was undetectable. 
Conclusion: Heterophilic abs like 
Rheumatoid Factor (RF) or HAMA are human 
abs that interact with assay abs. In 2-site 
immunometric “sandwich complex” assays, 
they often generate false-positive results. 
Those with RA are at risk of interference from 
RF or they can generate abs from exposure 
to immunotherapies that use chimeric abs. 
Adalimumab is a fully human monoclonal 
ab, so not expected to result in production of 
HAMA. The assay interference in this case 
is likely due to either RF or HAMA from an 
unknown source.  
https://doi.org/10.32873/unmc.dc.gmerj.1.1.065
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Background: Most common tumors in 
thyroid are well differentiated thyroid 
malignancies (Papillary and Follicular). 
Metastasis to thyroid gland are rare despite 
thyroid being a very vascular organ. Lung 
cancer commonly metastasize to liver, 
adrenals, brain and bones. Here we present 
a rare case of non-small cell lung cancer 
metastasis to a previously benign thyroid 
nodule.
Methods: An elderly patient was followed at 
the Endocrine clinic for multinodular goiter 
for several years. The patient had biopsy of 
these nodules multiple times in the past and 
have been benign. In 2016, the patient was 
diagnosed with large cell lung cancer and was 
treated with resection and chemotherapy. 
In 2017, an ultrasound showed increase in 
size of the right thyroid nodule. The patient 
underwent FNA and it showed indeterminate 
results with rare atypical cells suspicious of 
carcinoma. It was sent for molecular testing 
and it was negative for thyroid malignancy. 
Results: The slides were reviewed by the 
pathologist again and compared to the 
prior lung tumor specimens and it showed 
similar features to the lung carcinoma. CT 
scan showed prominent thyroid mass with 
enlarged paratracheal lymph node. The 
patient underwent total thyroidectomy and 
lymph node removal for definitive diagnosis. 
Pathology confirmed non-small cell lung 
carcinoma. 
Conclusions: In a patient with another known 
primary cancer, metastasis to thyroid should 
be considered in the differential of thyroid 
nodule. Imaging alone will not differentiate 
between primary and secondary thyroid 
malignancies. Molecular markers for thyroid 
cancer if negative do not rule out metastasis 
from another primary malignancy. FNAC 
with histochemistry and comparing to primary 
tumor help make the diagnosis. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.066
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Introduction: The incidence of pancreatic 
cancer is on the rise and continues to have a 
poor overall survival despite advancement in 
treatment strategies. The effect of sarcopenia 
on the prognosis of patients with pancreatic 
cancer is unknown. 
Methods: We performed a single-center 
retrospective study at our institution by 
measuring muscle mass among patients with 
pancreatic cancer from CT scan at initial 
diagnosis and at 8 weeks post-treatment. 
The results were stratified based on the 
57 
percentage of muscle loss (<10% and >10%) 
to determine whether sarcopenia impacted 
outcomes primarily, overall survival (OS) and 
progression-free survival (PFS).
Results: This retrospective study included 
162 patients from the University of Nebraska 
medical center diagnosed between 2009 and 
2017 with stage I-IV pancreatic cancer. We 
calculated hazard ratios (HRs) to evaluate 
the associations of overall survival with 
sarcopenia. There is a significant association 
between improved OS and PFS among those 
with less intensive reduction in muscle mass 
(p=0.038, p=0.027 respectively). However, 
no significant association of BMI loss with 
overall mortality on either OS or PFS (p=0.80, 
p=0.65).
Conclusion: The presence of sarcopenia may 
be a predictor of prognosis among patients 
with pancreatic cancer. A better understanding 
of the molecular mechanisms of sarcopenia 
might help improve survival outcomes in 
pancreatic cancer. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.067
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